Calton & Associates’s Aurinia Pharmaceuticals AUPH Stock Holding History

Calton & Associates’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-2,000	Closed	-$11K	–	402
2017 Q4	$11K	Buy	+2,000	New	+$11.1K	﹤0.01%	1032

Other funds holding AUPH

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Calton & Associates's AUPH Position: Q1 2018 in Review

Calton & Associates sold out of Aurinia Pharmaceuticals (AUPH) in Q1 2018, closing a stake of 2,000 shares — an estimated $11K sold.

Calton & Associates first reported a position in AUPH in Q4 2017 and held it in 1 quarter. The position peaked at $11K in Q4 2017. 64 funds tracked by Wall St. Rank hold AUPH as of Q1 2018.

Calton & Associates reported no remaining Aurinia Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Calton & Associates sold 2,000 Aurinia Pharmaceuticals shares in Q1 2018, an estimated $11K.
Calton & Associates first reported a position in Aurinia Pharmaceuticals in Q4 2017 and held it in 1 quarter.
Calton & Associates's Aurinia Pharmaceuticals position peaked at $11K in Q4 2017.
64 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2018.

Based on Calton & Associates's 13F filing for Q1 2018, filed 17 Apr 2018.